Monday, 29 June 2009
Tuesday, 23 June 2009
EFCG and AIME introduce manufacturing guidelines
Cefic's European Fine Chemicals Group (EFCG) and the Agrochemical & Intermediates Manufacturers in Europe (AIME) have launched a set of voluntary guidelines for manufacturers in the non-GMP, ISO-regulated fine chemicals industry. The guidelines set out minimum requirements to help promote the highest level of risk management in the manufacturing of non-GMP intermediates, active ingredients and end products.
EFCG
Monday, 22 June 2009
Helsinn plans Swiss expansion; completes Irish sale
Helsinn is planning to expand its development and manufacturing facilities at its Biasca, Switzerland, site. The expansion will build on the €5m investment in recent years. In addition, Helsinn has sold its Mulhuddart, Ireland facility to Milan, Italy, based Medinco C.F.M. Group.
InvestEgate
Sunday, 21 June 2009
Biologics to dominate pharma sales by 2014
Six of the 10 top selling drugs will be biologics by 2014, demonstrating the increasing dominance of biologic products, especially those for cancer treatment says EvaluatePharma. In 2000 only one of the top 10 was a biologic product.
EvaluatePharma
Wednesday, 17 June 2009
Monday, 15 June 2009
Boehringer and Kemwell collaborate on Indian biologics facility
Boehringer Ingelheim is working with Kemwell Pharma on a new biologics custom manufacturing facility in Bangalore, India. Boehringer will provide process technology and its BI-HEX expression system.
In-Pharma Technologist
Thursday, 11 June 2009
Angel reduces losses, sees positive future
Angel Biotechnology reported a pre-tax loss of almost £1.1m in 2008 as revenues rose 8% to £952,926. The company sees better prospects for 2009 and 2010 as it has recently signed three major contracts, with a value of £2.2m and its prospective new business pipeline is the best it has seen to date.
RTT News
Tuesday, 9 June 2009
Monday, 8 June 2009
Synthetech reports boost in earnings, gloomy outlook
Synthetech saw its earnings rise from $113,000 to $657,000 in its fourth quarter. However the company said the biopharmaceuticals market is showing some weakness, the difficult financing environment could impair drug development projects and that some major pharmaceutical companies are reducing their outsourcing expenses.
Portland Business Journal
Corden PharmaChem to close Cork facility
Corden PharmaChem is to close its Little Island, Cork, Ireland, facility later this year. The company has blamed the current API market conditions, limited potential for the development and commercialisation of new products, the scale of the plant and the significant capital investment necessary for it.
Irish Examiner
Johnson Matthey sees fine chemicals growth
In its year ended 31 March Johnson Matthey saw sales for its Fine Chemicals and Catalysts division grow 15% mostly due to favourable exchange rates. The division's Fine Chemicals businesses, Macfarlan Smith, Pharmaceutical Materials and Services and Research Chemicals which will report as a separate unit next year, contributed £220 (36%) of the division's revenue and 68% of the operating profit. Matthey reported that sales of some products were strong, but manufacturing costs, particularly the cost of energy, rose and that revenue from contract research was adversely affected by the lack of venture capital funding for a number of our smaller customers.
Manufacturing Chemist
Tuesday, 2 June 2009
SAFC in supply chain deal with Cherokee
Cherokee Pharmaceuticals will provide analytical testing, storage, packaging and distribution services for raw materials sourced by SAFC as part of a partnership agreement. The partnership will combine SAFC's global sourcing and production capabilities and with Cherokee's analytical laboratories, large-scale cGMP manufacturing, warehousing and distribution facilities.
In-Pharma Technologist
Lonza negotiating Genome Valley agreement
Further to previous reports Lonza said it is currently negotiating with the Andhra Pradesh Industrial Infrastructure Corporation Ltd for the acquisition or lease of 30 acres of land in Genome Valley. Lonza plans to establish an R&D and manufacturing facility on the site.
Lonza
